- $35.11m
- $29.69m
- $51.87m
- 42
- 36
- 73
- 48
Annual income statement for IRIDEX, fiscal year end - December 30th, USD millions except per share, conversion factor applied.
2019 December 28th | 2021 January 2nd | 2022 December 31st | 2022 January 1st | 2023 December 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 43.4 | 36.3 | 57 | 53.9 | 51.9 |
Cost of Revenue | |||||
Gross Profit | 17.9 | 15.6 | 25.4 | 22.8 | 21.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 52.4 | 42.9 | 64.5 | 58.9 | 61.9 |
Operating Profit | -8.97 | -6.58 | -7.54 | -5.03 | -10 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.77 | -6.3 | -7.48 | -5.18 | -9.48 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.81 | -6.33 | -7.55 | -5.22 | -9.57 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.81 | -6.33 | -7.55 | -5.22 | -9.57 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.81 | -6.33 | -7.55 | -5.22 | -9.57 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.643 | -0.457 | -0.474 | -0.444 | -0.593 |